UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 282

Sortiert nach

Daclatasvir plus Sofosbuvir plus Ribavirin for 12 or 16 Weeks in Treatment-Experienced Patients with HCV Genotype 3 Infection and Advanced Fibrosis or Cirrhosis

Journal of hepatology, 2016, Vol.64 (2), p.S753-S754

2016

Link zum Volltext

Verfügbarkeit prüfen

P0893 : Resistance analysis of treatment-experienced genotype 1 and 3 HCV infected patients treated with sofosbuvir in combination with GS-5816 +/− ribavirin for 12 weeks

Journal of hepatology, 2015-04, Vol.62, p.S678-S678

2015

Link zum Volltext

Verfügbarkeit prüfen

Very high real-world efficacy of ritonavir boosted paritaprevir with ombitasvir and dasabuvir +/− ribavirin in hepatitis C genotype 1 in patients with advanced fibrosis –Final results of the REV1TAL study

Journal of hepatology, 2017, Vol.66 (1), p.S521-S521

2017

Link zum Volltext

Verfügbarkeit prüfen

High sustained virologic response rates in patients with chronic hepatitis C virus GT1, 2 or 3 infection following 16 weeks of MK-3682/grazoprevir/ruzasvir plus ribavirin after having failed 8 weeks of a triplet drug regimen (Part C of C-CREST-1 & 2)

Journal of hepatology, 2017, Vol.66 (1), p.S306-S307

2017

Link zum Volltext

Verfügbarkeit prüfen

MAGELLAN-1, Part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic hepatitis C virus genotype 1 or 4 and prior direct-acting antiviral treatment failure

Journal of hepatology, 2017, Vol.66 (1), p.S83-S84

2017

Link zum Volltext

Verfügbarkeit prüfen

Real World Evaluation of Viekira Pak (Ritonavir Boosted Paritaprevir, Ombitasvir and Dasabuvir +/− Ribavirin) in HCV Genotype 1 Targeting Advanced Liver Disease (The Revital Study)

Journal of hepatology, 2016, Vol.64 (2), p.S780-S780

2016

Link zum Volltext

Verfügbarkeit prüfen

LO5 : Sofosbuvir + peginterferon/ribavirin for 12 weeks vs sofosbuvir + ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: The boson study

Journal of hepatology, 2015-04, Vol.62, p.S259-S260

2015

Link zum Volltext

Verfügbarkeit prüfen

Fas-mediated hepatocyte apoptosis is increased by hepatitis C virus infection and alcohol consumption, and may be associated with hepatic fibrosis: mechanisms of liver cell injury in chronic hepatitis C virus infection

Journal of viral hepatitis, 2001-11, Vol.8 (6), p.406-413

2001

Link zum Volltext

Verfügbarkeit prüfen

High Efficacy of an 8-Week 3-Drug Regimen of Grazoprevir/MK-8408/MK-3682 in HCV Genotype 1, 2 and 3-Infected Patients: SVR24 Data from the Phase 2 C-Crest 1 and 2 Studies

Journal of hepatology, 2016, Vol.64 (2), p.S759-S759

2016

Link zum Volltext

Verfügbarkeit prüfen

Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting

Journal of viral hepatitis, 2006-05, Vol.13 (5), p.311-315

2006

Link zum Volltext

Verfügbarkeit prüfen

61 TREATMENT WITH SOFOSBUVIR + RIBAVIRIN FOR 12 WEEKS ACHIEVES SVR12 OF 78% IN GT2/3 INTERFERON-INELIGIBLE, -INTOLERANT, OR -UNWILLING PATIENTS: RESULTS OF THE PHASE 3 POSITRON TRIAL

Journal of hepatology, 2013-04, Vol.58, p.S28-S28

2013

Link zum Volltext

Verfügbarkeit prüfen

64 GS-5885 + GS-9451 + PEGINTERFERON AND RIBAVIRIN (PR) FOR SIX OR TWELVE WEEKS ACHIEVES HIGH SVR12 RATES IN TREATMENT-NAÏVE GENOTYPE 1 IL28B CC PATIENTS

Journal of hepatology, 2013-04, Vol.58, p.S29-S29

2013

Link zum Volltext

Verfügbarkeit prüfen

Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin

Journal of viral hepatitis, 2013-04, Vol.20 (4), p.e115-e123

2013

Link zum Volltext

Verfügbarkeit prüfen

514 IL28B GENOTYPE IS NOT USEFUL FOR PREDICTING TREATMENT OUTCOME IN ASIAN CHRONIC HEPATITIS B (CHB) PATIENTS TREATED WITH PEGYLATED-INTERFERON-A (PIFN)

Journal of hepatology, 2012-04, Vol.56, p.S203-S203

2012

Link zum Volltext

Verfügbarkeit prüfen

Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3

Journal of viral hepatitis, 2012-09, Vol.19 (9), p.623-634

2012

Link zum Volltext

Verfügbarkeit prüfen

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

The New England journal of medicine, 2015-12, Vol.373 (27), p.2608-2617

2015

Link zum Volltext

Verfügbarkeit prüfen

53 RELATION BETWEEN SUSTAINED VIROLOGIC RESPONSE AND INSULIN RESISTANCE IN PATIENTS WITH GENOTYPE 1 OR 2/3 CHRONIC HEPATITIS C

Journal of hepatology, 2010, Vol.52, p.S25-S25

2010

Link zum Volltext

Verfügbarkeit prüfen

287 EVALUATING VIROLOGIC RESPONSE WITHIN 2–4 WEEKS HAS HIGH POSITIVE/NEGATIVE PREDICTIVE VALUES FOR SUSTAINED VIROLOGIC RESPONSE IN PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C DURING TREATMENT

Journal of hepatology, 2010, Vol.52, p.S120-S120

2010

Link zum Volltext

Verfügbarkeit prüfen

The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C

Journal of viral hepatitis, 2003-01, Vol.10 (1), p.16-22

2003

Link zum Volltext

Verfügbarkeit prüfen

817 POSITIVE PREDICTIVE VALUE OF EARLY ANTIVIRAL RESPONSE PROFILE WITH ALBINTERFERON ALFA-2B IN IFN-NAIVE PATIENTS WITH GENOTYPE 1, CHRONIC HEPATITIS C

Journal of hepatology, 2008, Vol.48, p.S306-S306

2008

Link zum Volltext

Verfügbarkeit prüfen

819 HEALTH-RELATED QUALITY OF LIFE (HRQOL) WITH ALBINTERFERON ALFA-2B PLUS RIBAVIRIN IN IFN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C

Journal of hepatology, 2008, Vol.48, p.S306-S307

2008

Link zum Volltext

Verfügbarkeit prüfen

Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options

The New England journal of medicine, 2013-05, Vol.368 (20), p.1867-1877

2013

Link zum Volltext

Verfügbarkeit prüfen

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

The Lancet (British edition), 2019-12, Vol.394 (10215), p.2184-2196

2019

Link zum Volltext

Verfügbarkeit prüfen

Treatment of hepatitis C with interferon and ribavirin

Journal of gastroenterology and hepatology, 2000-06, Vol.15 (6), p.581-586

2000

Link zum Volltext

Verfügbarkeit prüfen

Chronic hepatitis B: new therapies on the horizon?

The Lancet (British edition), 1999-11, Vol.354 (9191), p.1662-1663

1999

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 282

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(217)
Mit Volltextzugriff
(251)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(281)
Japanisch
(13)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(112)
Life Sciences & Biomedicine
(81)
Humans
(66)
Male
(49)
Female
(45)
Middle Aged
(43)
Gastroenterology & Hepatology
(35)
Adult
(33)
Aged
(27)
Hepatitis C, Chronic - Drug Therapy
(25)
Technology
(25)
Gastroenterology And Hepatology
(24)
Antiviral Agents - Therapeutic Use
(23)
Treatment Outcome
(22)
Infectious Diseases
(21)
Physical Sciences
(21)
Biological And Medical Sciences
(20)
Medical Sciences
(20)
Oncology
(19)
Engineering
(18)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Daclatasvir plus Sofosbuvir plus Ribavirin for 12 or 16 Weeks in Treatment-Experienced Patients with HCV Genotype 3 Infection and Advanced Fibrosis or Cirrhosis

P0893 : Resistance analysis of treatment-experienced genotype 1 and 3 HCV infected patients treated with sofosbuvir in combination with GS-5816 +/− ribavirin for 12 weeks

Very high real-world efficacy of ritonavir boosted paritaprevir with ombitasvir and dasabuvir +/− ribavirin in hepatitis C genotype 1 in patients with advanced fibrosis –Final results of the REV1TAL study

High sustained virologic response rates in patients with chronic hepatitis C virus GT1, 2 or 3 infection following 16 weeks of MK-3682/grazoprevir/ruzasvir plus ribavirin after having failed 8 weeks of a triplet drug regimen (Part C of C-CREST-1 & 2)

MAGELLAN-1, Part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic hepatitis C virus genotype 1 or 4 and prior direct-acting antiviral treatment failure

Real World Evaluation of Viekira Pak (Ritonavir Boosted Paritaprevir, Ombitasvir and Dasabuvir +/− Ribavirin) in HCV Genotype 1 Targeting Advanced Liver Disease (The Revital Study)

LO5 : Sofosbuvir + peginterferon/ribavirin for 12 weeks vs sofosbuvir + ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: The boson study

Fas-mediated hepatocyte apoptosis is increased by hepatitis C virus infection and alcohol consumption, and may be associated with hepatic fibrosis: mechanisms of liver cell injury in chronic hepatitis C virus infection

High Efficacy of an 8-Week 3-Drug Regimen of Grazoprevir/MK-8408/MK-3682 in HCV Genotype 1, 2 and 3-Infected Patients: SVR24 Data from the Phase 2 C-Crest 1 and 2 Studies

Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting

61 TREATMENT WITH SOFOSBUVIR + RIBAVIRIN FOR 12 WEEKS ACHIEVES SVR12 OF 78% IN GT2/3 INTERFERON-INELIGIBLE, -INTOLERANT, OR -UNWILLING PATIENTS: RESULTS OF THE PHASE 3 POSITRON TRIAL

64 GS-5885 + GS-9451 + PEGINTERFERON AND RIBAVIRIN (PR) FOR SIX OR TWELVE WEEKS ACHIEVES HIGH SVR12 RATES IN TREATMENT-NAÏVE GENOTYPE 1 IL28B CC PATIENTS

Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin

514 IL28B GENOTYPE IS NOT USEFUL FOR PREDICTING TREATMENT OUTCOME IN ASIAN CHRONIC HEPATITIS B (CHB) PATIENTS TREATED WITH PEGYLATED-INTERFERON-A (PIFN)

Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

53 RELATION BETWEEN SUSTAINED VIROLOGIC RESPONSE AND INSULIN RESISTANCE IN PATIENTS WITH GENOTYPE 1 OR 2/3 CHRONIC HEPATITIS C

287 EVALUATING VIROLOGIC RESPONSE WITHIN 2–4 WEEKS HAS HIGH POSITIVE/NEGATIVE PREDICTIVE VALUES FOR SUSTAINED VIROLOGIC RESPONSE IN PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C DURING TREATMENT

The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C

817 POSITIVE PREDICTIVE VALUE OF EARLY ANTIVIRAL RESPONSE PROFILE WITH ALBINTERFERON ALFA-2B IN IFN-NAIVE PATIENTS WITH GENOTYPE 1, CHRONIC HEPATITIS C

819 HEALTH-RELATED QUALITY OF LIFE (HRQOL) WITH ALBINTERFERON ALFA-2B PLUS RIBAVIRIN IN IFN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C

Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Treatment of hepatitis C with interferon and ribavirin

Chronic hepatitis B: new therapies on the horizon?

Suchergebnisse filtern